Information Provided By: 
Fly News Breaks for January 13, 2020
AZN, AMRN
Jan 13, 2020 | 09:07 EDT
JPMorgan analyst Jessica Fye views the removal of Epanova as a positive for Amarin (AMRN). AstraZeneca (AZN) said this morning that it is closing the Phase III trial for Epanova in mixed dyslipidaemia following the recommendation from an independent Data Monitoring Committee. Epanova is an omega-3 carboxylic acid and was being studied to demonstrate a possible benefit in patients with mixed dyslipidaemia who are at increased risk of cardiovascular disease. Shares of Amarin are up 6%, or $1.07, to $20.02 in premarket trading.
News For AMRN;AZN From the Last 2 Days
AZN
Apr 18, 2024 | 09:41 EDT
Unusual total active option classes on open include: Wrap Technologies (WRAP), AstraZeneca (AZN), JetBlue (JBLU), United Continental (UAL), Taiwan Semi (TSM), Nokia (NOK), EBay (EBAY), Maplebear Inc (CART), Airbnb (ABNB), and UnitedHealth (UNH).
